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SUMMARY
Background: Antimalarial drug resistance has been a 
major contributor to the failure of the battle against 
malaria in many developing countries. The P. 
falciparum genes, pfcrt and pfmdr-1, have been 
implicated in chloroquine resistance.  The objective of 
this study was to determine the presence of mutant 
alleles of these chloroquine resistance genes among 
isolates of P. falciparum from children presenting with 
severe malaria in Ghana.
Methods: Venous blood samples were taken from 
patients, and plasma chloroquine levels measured. P. 
falciparum chromosomal DNA was isolated from the 
blood samples, and subjected to PCR, restriction 
digestion and sequencing. Resulting data were analysed 
using the STATA statistical software.
Results: Of 140 children recruited into the study, 109 
(77.9%) had detectable pre-treatment chloroquine 
levels. PCR and restriction digestion analysis of the 
pfcrt gene indicated that 124 (88.6%) had the mutant 
T76 gene, and that this correlated with higher 
chloroquine levels. Sequence analysis of these showed 
consistent genetic sequences for chloroquine resistant 
and sensitive parasites with respect to Pfcrt codons 72 
through 76.The Pfcrt T76 mutation was found in 88.4% 
of isolates having the Pfmdr-1Y86 mutation. The 
Pfmdr-1 Y86 mutation was found in 67.6% of isolates 
having the Pfcrt T76 mutation.
Conclusion: The study affirms Pfcrt as a better 
chloroquine resistance marker. Both mutations are 
independently selected by chloroquine levels and that 
one mutation (Y86) might modify/increase the effect of 
the other (T76). This study also depicts the much-
overlooked antimalarial drug resistance situation in the 
area and emphasizes the need for a proper treatment 
strategy.
Keywords: Plasmodium falciparum, chloroquine (CHQ), 
pfcrt, pfmdr-1, mutation.
INTRODUCTION
Malaria affects approximately 40% of the world's 
population especially those living in the world's poorest 
nations.1 Ninety per cent of deaths due to malaria occur 
in Africa, south of the Sahara, with majority of the 
cases being young children, with an African child 
dying of the disease every 30 seconds.2
Shortages of resources undeniably remain the 
significant obstacles to malaria control in several 
developing countries, but drug resistance has been a 
major additional contributor to the failure of the battle 
against the disease in many of these countries.3 As a 
matter of fact, the continuous changing patterns of drug 
resistance necessitate the use of drugs that are more 
expensive and may have dangerous side effects. 
Artemisinin and its derivatives have, in the past 
decade, become the first line of treatment in some parts 
of the world.4 However, their indiscriminate use for 
self-treatment of suspected uncomplicated malaria may 
also be ringing the alarm bell for the development of 
resistance to them in the ensuing decade.5
Resistance of Plasmodium falciparum to chloroquine 
(CHQ), the best known of the 4-aminoquinolones, was 
first noted in the late 1950s from Colombia and 
Thailand.6 Reports of similar resistance patterns 
quickly followed from other countries in South 
America and South East Asia, with the first well-
documented case of chloroquine-resistant P. 
falciparum in Africa, reported from Kenya in 1979 by 
Kean in a tourist.6 Soon afterwards chloroquine 
resistance was seen in other countries in East Africa 
and later spread with increasing frequency throughout 
most of Africa.6,7 Chloroquine resistance has since 
spread across Africa and now only a few countries in 
the tropics are unaffected. In Ghana, chloroquine 
resistance has been reported.8
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Extensive research has revealed that resistance to 
chloroquine occurs via an active energy-dependent 
process of efflux of chloroquine from the P. falciparum
parasite cells, and that this involves a number of genes, 
namely, P. falciparum multi-drug resistance (pfmdr-1) 
and P. falciparum chloroquine resistance transporter 
(pfcrt) genes which are located on chromosomes 5 and 
7 respectively.6,9-12 A mutation of Asparagine to 
Tyrosine at amino acid position 86 (N86Y) of the 
pfmdr-1 with or without other mutations at other 
positions within this gene correlate well with 
chloroquine resistance, whereas within the pfcrt gene, a 
mutation of Lysine to Threonine at amino acid position 
76 (K76T) with or without other mutations within this 
gene have also been implicated.6,10-12
In Ghana, malaria is the most frequent cause of 
morbidity and mortality and constitutes approximately 
40% of all out-patient department diagnosis across the 
country, with 25% of all childhood deaths attributable 
to malaria.13,14 Early treatment failure rates with 
chloroquine in five out of six districts studied in Ghana 
were above 25%, with three of them above 45%.15,16
The study was carried out to elucidate the presence of 
genetic markers of chloroquine resistance in P. 
falciparum strains in relation to plasma chloroquine 
levels among infants presenting to the Komfo Anokye 
Teaching Hospital with severe malaria.
MATERIALS AND METHODS
Study design
This study was carried out during the end of the high 
malaria season and the beginning of the low malaria 
season i.e. November to February, at the Komfo 
Anokye Teaching Hospital, a tertiary referral centre in 
Ghana’s second largest city, Kumasi, with over 7,500 
admissions per year and wards running at well over 
150% bed occupancy (KATH Statistics, 2002). 
Paediatric patients, aged 4 to 120 months, were 
recruited into the study if they had clinical signs and 
symptoms suggestive of severe malaria based on World 
Health Organisation (WHO) criteria (17), and together 
with the presence of a blood film positive for asexual 
stages of P. falciparum. These included those with: 
unarousable coma, i.e. a Blantyre coma score of 2 or 
less; severe anaemia, of haemoglobin level of <5 g/dl 
or a haematocrit of <15%; severe respiratory distress, 
being the presence of intercostal and/ or sub-costal 
recession or deep acidotic breathing; prostration, being 
the inability to sit upright in a child normally able to do 
so, or if younger, an inability to drink or breastfeed.
Children with evidence of other diagnosis such as 
meningitis, pneumonia or renal failure were excluded 
from the study for ethical reasons. Detailed 
demographical data and clinical history were taken.
Blood samples, chloroquine levels and isolation of 
parasite DNA
In addition to the routine blood samples, 1 ml of 
venous blood was taken into lithium heparin tubes, and 
cellular and plasma components separated by 
centrifugation. The plasma was stored at –70°C, and an 
equivalent volume of 8 M urea/100 mM EDTA added 
to the red cell pellet and stored at 4°C.
Chloroquine levels in plasma were measured by an 
enzyme-linked immunosorbent assay (ELISA) method 
using monoclonal antibodies.18 Chloroquine levels of 
>100 ng/ml indicated recent chloroquine use of 
therapeutic dosage. The lower limit of detection was 5 
ng/ml. Chromosomal DNA of P. falciparum was 
isolated from the Urea/EDTA venous blood samples 
taken from patients recruited, using the DNeasy tissue 
kit (Qiagen) according to manufacturer’s instructions.
PCR Amplification of pfcrt and pfmdr-1 genes
Polymerase chain reactions (PCRs) were done using 
Biometra® Thermocycler (Biometra - Göttingen, 
Germany). Seven (7) primer pairs were designed to 
amplify the whole of the pfmdr-1 gene at different 
points along its length. This was aimed at identifying 
new mutations that may exist in the Ghanaian strains of 
the P. falciparum. The segment of the pfcrt gene 
containing the polymorphisms at positions 72 through 
76 was amplified through firstly an outer PCR, 
followed by a nested PCR with two primer pairs. All 
primers were designed using the 47573 base pair linear 
DNA sequence of the P. falciparum Chloroquine 
resistant strain Dd2/Indochina, as given by Pub Med 
accession number AF030694.
Restriction Digest of pfcrt gene amplicons
Enzymatic digestion of the resulting 145 base pair 
fragment at codon 76 of the pfcrt amplicons was done 
using Apo-1 restriction enzyme (New England 
BioLabs ) according to manufacturer’s instructions. 
This yielded two fragments of 31 and 114 base pairs in 
the case of the parasite strains containing the wild K76 
variant, whereas the mutant T76 variant yielded one 
fragment since there was no digestion. 
Nucleotide sequencing
Sequencing of the resulting DNA amplicons was 
performed with Taq polymerase-catalyzed cycle 
sequencing using fluorescent-labelled BigDye 
terminator kits, according to manufacturer’s 
instructions, in an ABI 310 Genetic Analyser (Perkin-
Elmer, UK). 
June 2010 Volume 44, Number 2 GHANA MEDICAL JOURNAL
54
The aforementioned primers were used to sequence the 
amplicons in both the forward and reverse directions of 
both the pfcrt and the pfmdr-1 genes.
Bio-Informatic Analyses
The Sequencing Analysis software for analysis of raw 
data produced by the ABI Prism genetic analyzer 
instruments was used. The software calculates the 
electropherograms from multicolour traces, which 
allow the data to be inspected visually for mutations.
Using the ABI Prism genetic analysis software, the 
resulting sequences were compared to the 47573 
basepair linear DNA sequence of the P. falciparum
Chloroquine resistant strain Dd2/Indochina, given by 
PubMed accession number AF030694.
Statistical Analyses
Resulting data were analysed using the STATA data 
analysis and statistical software.
Ethical Clearance
Ethical clearance for the study was obtained from the 
Research and Ethics Committee of the School of 
Medical Sciences, Kwame Nkrumah University of 
Science and Technology, Kumasi, Ghana. Written 
informed consent to participate was obtained from the 
parent/guardian of each child after explaining to 




Blood samples of 140 children, all diagnosed with 
severe malaria, were available for analysis. They 
comprised 55% (77) males and 45% (63) females.
Their ages ranged from 4 months to 120 months, with a 
median age of 21 months and a mean age of 28.40 
months.
Pre-treatment plasma chloroquine levels
Of the 140 children presenting with severe malaria to 
the Komfo Anokye Teaching Hospital, 109 (77.9%) 
had detectable pre-treatment plasma chloroquine 
levels, whilst the remaining 31 (22.1%) had no 
detectable plasma chloroquine.
Only 45 (32.1%) of them had therapeutic chloroquine 
levels of above 100 ng/ml indicating recent 
chloroquine use of therapeutic dosage, with the 
remaining 95 (67.9%) having sub-therapeutic 
chloroquine levels. The median chloroquine level was 
68 ng/ml, with no significant differences in 
chloroquine levels with respect to age groups 
(p=0.002).
Analysis of molecular markers of chloroquine 
resistance
Parasite DNA was successfully extracted from all the 
140 blood samples and analyzed for pfcrt and pfmdr-1 
genetic markers of chloroquine resistance.
Analysis of pfcrt gene
Two rounds of PCR namely, outer and nested PCR, 
yielded a 145bp PCR product for each of the 140 
samples. These products contained the codons of 
interest, 72 through 76, which were analyzed both by 
enzymatic digestion and sequencing. A photo of 
agarose gel electrophoresis of 46 samples is shown in 
Figure 1.
Figure 1 | Agarose gel electrophoresis photo of PCR 
amplification of the pfcrt genes of samples 1-46, positive and 
negative controls are indicated +/- respectively. All 46 
samples shown in this photo yielded positive amplification of 
the pfcrt gene with a size of 145 bp. These PCR amplicons 
were later subjected to Apo-I enzymatic digestion.
Apo-1 enzymatic digestion of the resulting 145 bp 
fragment at codon 76 yielded two fragments of 31 and 
114 base pairs in the case of the parasite strains 
containing the wild K76 variant, whereas the mutant 
T76 variant yielded only one fragment since there was 
no digestion. Multi-clonal variants yielded three 
fragments (145, 114, and 31 bp products). Restriction 
digest of the 140 samples gave the following results: 
123 (87.9%) mutant types, 14 (10%) wild types and 3 
(2.1%) mixed infections, which were also confirmed by 
sequencing [see Figures 2 and 3].
Figure 2 | Apo-1 restriction digestion and pfcrt genotype 
distribution among the 140 P. falciparum samples. 123
(87.9%) mutant types, 14 (10%) wild types and 3 (2.1%) 
mixed infections, which were also confirmed by sequencing.
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Genetic sequences of the isolates from each of the 140 
blood samples were determined using the ABI Prism 
genetic sequencer. Visual inspection of the sequence 
along the length of the gene was done. No new 
mutations were observed in the pfcrt gene, except for 
the known mutant codons of S72, M74, N75, and T76. 
All the 123 mutant samples that showed single bands 
with Apo-1 digestion (mutants) had a nucleotide 
change of adenine (A) to cytosine (C) at nucleotide 
position 227, indicating an amino acid substitution of 
lysine with a threonine at amino acid position 76 of the 
pfcrt gene [see Figure 3]. The 14 wild types did not 
show any nucleotide change, whilst the 3 mixed 
isolates showed the presence of both adenine (A) and 
cytosine (C) peaks at nucleotide position 227.
Figure 3 | Sequence chromatographs of a wild type (A) and a 
mutant type (B) pfcrt genes. Each of the coloured peaks 
indicates a nucleotide, duly translated directly above each 
peak, and aligned with the pfcrt template sequence of the Dd2 
mutant isolate in the upper window. Both the forward and the 
reverse sequences are represented, with a dash (-) beneath a 
nucleotide indicating conformity and an asterix (*) indicating 
non-conformity.  The nucleotide positions are indicated in 
figures as 210 through 230. The amino acids at positions 74, 
75 and 76 are indicated as M, N and K76 respectively on the 
wild type chromatograph, and as I, E and T76 on the mutant 
type chromatograph.
The distribution of these pfcrt genotypes with respect 
to chloroquine levels are represented in Table 1. It was 
observed that plasma chloroquine levels were 
significantly higher (p=0.001) among patients with the 
mutant variant of the pfcrt gene [median CHQ level-
76.0 ng/L, mean CHQ level-95.1 ng/L] than among 
those with the wild type [median CHQ level-0.0ng/L, 
mean CHQ level-51.0ng/L] or the mixed or multi-
clonal isolates [median CHQ level-0.0 ng/L, mean 
CHQ level-0.0 ng/L].
Table 1 | pfcrt genotype distribution and plasma 
chloroquine levels. plasma chloroquine levels were 
significantly higher (p=0.001) among patients with the 
mutant variant of the pfcrt gene [median CHQ level-76.0 
ng/L, mean CHQ level-95.1 ng/L] than among those with the 
wild type [median CHQ level-0.0ng/L, mean CHQ level-
51.0ng/L] or the mixed or multi-clonal isolates [median CHQ 











>300 1 5 0
201-300 0 13 0
101-200 1 25 0
5-100 4 60 0
<5 8 20 3
Total 14 123 3
Analysis of pfmdr gene
Seven (7) primer pairs were designed to amplify the 
whole of the Pfmdr-1 gene at different points along its 
length. This was aimed at identifying new mutations 
that may exist in the Ghanaian strains of the P. 
falciparum. Mutations were observed at three codon 
positions, namely, 1034, 1042, and 1246 of the pfmdr-1 
gene in forty-seven (47) isolates analyzed.
The 47 samples were subsequently analyzed for the 
N86Y and Y184F codons. Twenty six (26) of the 47 
samples carried the Y86 mutant codon, whereas 32 
carried the F184 mutant codon. Both mutations 
involved nucleotide substitution of adenine (A) with 
thymine (T) at positions 256 and 551 respectively, 
resulting in substitution of tyrosine (Tyr) for 
Asparagine (Asn) and Phenylalanine (Phe) for tyrosine 
(Tyr) respectively. 
Table 2 a and b | Correlation between the pfmdr-1Y86 






















Total 26 21 47*
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Analysis pfcrt and pfmdr genes
The relation between the Pfmdr-1 Y86 mutation and 
the Pfcrt T76 mutation was assessed. The presence of 
the T76 mutant gene in the Y86 mutant gene was 
stronger (p=0.002) than the reverse (see Tables 2a & 
b).
Presence of the Pfcrt T76 mutation in samples with the 
Pfmdr-1 Y86 mutation.
The presence of the T76 mutant gene in the Y86 mutant gene 


























Total 34 12 1 47*
Presence of the Pfmdr-1Y86 mutation in samples with the
Pfcrt T76 mutation.
The presence of the Y86 mutant gene in the T76 mutant gene 
was not strong.
*Sequences of remaining samples were not analyzed.
DISCUSSION
The results demonstrated the extent of pre-hospital 
treatment among the study population and the
widespread use of chloroquine. Although 50% of these 
babies had visited other health facilities prior to the 
onset of the severe malaria and their subsequent 
admission at the Komfo Anokye Teaching Hospital, 
the remaining 50% reported home treatment with 
chloroquine, which was consistent  with similar report 
from Kenya.19
Home management of suspected malaria among infants 
has been promoted all across malaria endemic areas by 
the WHO.20-24 Thus 77.9% of these children with
detectable chloroquine levels was a good indicator of 
the success in the fight against malaria deaths through 
home management among infants. However, with as 
high as 67.9% of them having sub therapeutic levels 
(i.e. 87.2% of those with detectable chloroquine 
levels), there is the need for increased awareness in 
proper home treatment of malaria among infants. A 
previous study indicated that only 3.7% of febrile 
infants were given appropriate treatment at home prior 
to hospitalization.24
Interviewing mothers in this study revealed that, in
practice, sub-therapeutic pre-hospitalization 
chloroquine levels could be attributed to either mothers 
not measuring medicines (syrups) accurately for their 
babies leading to improper dosing and under-dosage or 
most babies not swallowing all the medicines properly 
measured and administered to them orally by their 
mothers resulting in under-dosage.
There was no significant difference in chloroquine 
levels with respect to age of patient, which is 
inconsistent with previous reports from populations 
with uncomplicated malaria.25 However, as indicated in 
Table 1, the Pfcrt T76 mutant variant correlated with 
higher plasma chloroquine levels (p=0.001) which is 
consistent with the findings of May and Meyer.25
The two main methods, namely Apo-1 enzymatic 
digestion and the sequencing, employed here to 
analyze the pfcrt gene status of the parasite strains from 
the study participants served to confirm or complement 
findings from each of the methods. Sensitive strains, 
mutant strains and multi-clonal strains characterized 
using Apo-1 enzymatic digestion were duly confirmed 
by sequencing as shown in Figure 3.
The finding of 87.9% of patients harbouring the T76 
mutant strain far exceeds the documented chloroquine 
treatment failure of ≥25% of central Ghana.15 Although 
there is not much historical data and this finding is 
among only severe malaria patients, the pattern may 
well permit the hypothesis that chloroquine resistance 
contributes to the incidence of severe malaria. This is 
even so since the Pfcrt T76 strain correlated with 
higher plasma chloroquine levels.
The occurrence of mutations at three codons 1034,
1042, and 1246 of the pfmdr-1 gene in the 47 isolates 
downplayed the role of these codons in the 
determination of chloroquine resistance status. This 
could be the normal genetic code of the parasite strain 
of Kumasi. Emphasis was therefore laid only on the 
two codons of N86Y and Y184F.
It could be observed in Tables 2a & b that the presence 
of the Pfcrt T76 mutation confers a strong likelihood 
for the mutant Y86 of the pfmdr-1 to be present than 
the reverse (p=0.002); 88.5% of the Pfcrt T76 mutant 
strains also had the Pfmdr-1 Y86 point mutation as 
opposed to 67.6% of the Pfmdr-1 Y86 mutant strain 
harbouring the Pfcrt T76 point mutation. It is therefore 
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likely that the Y86 mutation modifies or increases the 
effect of T76.
CONCLUSION
The above data may indicate that inappropriate home 
treatment of malaria is a common thing within the 
Kumasi metropolis, which calls for improved education 
to ensure that patients are given the appropriate 
treatment when malaria is suspected. Again, the data 
have shown that chloroquine resistance among P. 
falciparum isolates in Kumasi is mediated by the pfcrt
and the pfmdr-1 genes. The two mutations, T76 and 
Y86, occurring on two different genes on two different 
chromosomes, are all true markers of chloroquine 
resistance, which are likely to be independently 
selected by plasma chloroquine levels. We can, 
however, conclude from this study that one mutation 
(Y86) might modify or increase the effect of the other 
(T76) as indicated by the strong presence of Pfcrt T76 
in Pfmdr-1 Y86 (p=0.002).
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